Skip to content 
LDS Church Abuse: Understanding the Issue & Seeking Justice | TheJusticeNow
Explore the complex issue of LDS Church abuse, survivor experiences, legal challenges, and how JusticeNow supports victims. Get a free, confidential case review.
Roundup Alternatives for Your Garden: Safe and Effective Replacements
Learn about LDS church child abuse allegations, survivor support, legal actions, and how to apply for a free, confidential case evaluation with The Justice Now.
LDS Church Child Abuse: Legal Help, Facts & Support | The Justice Now
Learn about LDS church child abuse allegations, survivor support, legal actions, and how to apply for a free, confidential case evaluation with The Justice Now.
Roundup Settlement: Legal Help for Cancer Claims | The Justice Now
Learn how the Roundup Settlement helps individuals diagnosed with cancer from glyphosate exposure. See if you qualify. Free legal case evaluations available.
Hailstorms Damage and Your Insurance Claim
But, did you know if your insurance companies are going to compensate for every damage caused by hail or windstorm?
Weight-loss drug developers line up to tap market worth $150 billion
Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are currently the leading weight loss pharmaceutical market, and they are expected to be worth around $150 billion by the beginning of the 2030s.
J&J must pay $260 million in latest talc lawsuit trial, Oregon jury says
In a Talc Lawsuit trial, Johnson & Johnson must pay $260 million to an Oregon woman who claimed she was diagnosed with mesothelioma, which is a fatal cancer that can be linked to asbestos exposure, after inhaling the talc powder of the company, the jury found on Monday.
US judicial panel approves rule governing federal mass torts
On Tuesday, a U.S. judicial panel approved the very first rule that governs federal mass tort cases. The rule will give judges a first plan that they can follow when asked to hear hundreds or even thousands of lawsuits against corporations.
J&J acquires experimental skin disorder drug for $1.25 billion
On Tuesday, J&J finalized a deal to obtain the rights to an innovative treatment for skin conditions from Numab Therapeutics, a privately held company, in a transaction valued at approximately $1.25 billion, marking its second significant agreement this month focused on addressing eczema.
Judge rejects key expert in paraquat lawsuits, tosses first cases set for trial
Paraquat lawsuits, An expert witness who is vital to cases claiming that Syngenta’s herbicide, paraquat, causes Parkinson’s disease is not able to be called in to testify in the courtroom the way a federal judge decided Wednesday, dissolving the first four lawsuits involving the product, which were scheduled to be tried.
